BDBM646016 (2S,4R)-4-hydroxy-1-((2S)-2-(3-(2-(4-((2-(2- hydroxyphenyl)-5,6,6a,7,9,10-hexahydro-8H- pyrazino[1',2':4,5]pyrazino[2,3-c]pyridazin-8- yl)methyl)piperidin-1-yl)ethoxy)isoxazol-5- yl)-3-methylbutanoyl)-N-((S)-1-(4-(4- methylthiazol-5-yl)phenyl)ethyl)pyrrolidine- 2-carboxamide (Mixture of Diastereomers at *)::US20240018158, Example 5
SMILES CC(C)[C@@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)c1cc(OCCN2CCC(CN3CCN4C(CNc5nnc(cc45)-c4ccccc4O)C3)CC2)no1
InChI Key InChIKey=YLJCDBUVZUOGKM-KEKVRLSESA-N
Data 1 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 1 hit for monomerid = 646016
TargetProbable global transcription activator SNF2L2(Homo sapiens (Human))
Prelude Therapeutics
US Patent
Prelude Therapeutics
US Patent
Affinity DataIC50: <100nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (PerkinElmer ProxiPlate Plu...More data for this Ligand-Target Pair